On June 16, 2017, 107.3 million shares were listed on SIX.
On June 20, 2017, 11.8 million shares issued through the conversion of the first tranche of the convertible loan provided by Cilag Holding AG, an indirect subsidiary of Johnson & Johnson, were listed. On November 9, 2021, a second tranche of the convertible loan was converted and Cilag acquired 9.6 million shares of the Group.
On July 13, 2018, the Group privately placed 11.9 million new registered shares of CHF 0.05 par value from existing authorized capital at CHF 25.62 per new share, by way of an accelerated book-building process. Concurrently to the private placement of new shares, the Group issued CHF 200 million of senior unsecured convertible bonds on July 17, 2018. The Bonds mature on July 17, 2024 and are convertible into 5.9 million registered shares of the Group.
On May 20, 2020, the Group privately placed 11 million new registered shares of CHF 0.05 par value from existing authorized share capital at CHF 30 per new share, by way of an accelerated book-building process.
On October 22, 2020, the Group issued 23.8 million new registered shares of CHF 0.05 par value from existing authorized share capital at CHF 22.50 per new share through an at-market rights offering.
On July 28, 2021, the Group placed CHF 600 million senior unsecured convertible bonds due 2028 convertible into 19.0 million shares of the Group.
Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.
Idorsia is traded under the following symbols: Reuters IDIA.S / Bloomberg IDIA:SW.
